Clinical Trial Update: A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating MT1621 for Thymidine Kinase 2 deficiency was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymidine Kinase Deficiency

Drugs mentioned

• MT1621

Snippet

Sponsor: Zogenix MDS, Inc. | Conditions: Thymidine Kinase 2 Deficiency | Phase 3 | Status: WITHDRAWN